Wordt geladen...
A randomized, placebo‐ and sitagliptin‐controlled trial of the safety and efficacy of omarigliptin, a once‐weekly dipeptidyl peptidase‐4 inhibitor, in Japanese patients with type 2 diabetes
AIMS: To assess the safety and efficacy of omarigliptin in Japanese patients with type 2 diabetes (T2D). METHODS: In a 24‐week double‐blind trial, 414 patients with T2D were randomized to omarigliptin 25 mg once weekly, sitagliptin 50 mg once daily or placebo. The double‐blind period was followed by...
Bewaard in:
| Gepubliceerd in: | Diabetes Obes Metab |
|---|---|
| Hoofdauteurs: | , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Blackwell Publishing Ltd
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5655696/ https://ncbi.nlm.nih.gov/pubmed/28449368 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12988 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|